Study Purpose:
Amyotrophic lateral sclerosis (ALS) is a kind of motor neuron degeneration disorder without effective therapy. This registered cohort study will provide further insights into the clinical course of ALS, and investigate disease-relative risk factors and the genetic background of Chinese ALS patients.Study Status:
Recruiting
Disease:
Amyotrophic Lateral Sclerosis
Study Type:
Observational
Type of Intervention:
N/A
Intervention Name:
N/A
Placebo:
N/A
Phase:
N/A
Study Chair(s)/Principal Investigator(s):
Ning Wang, MD,PhD, First Affiliated Hospital of Fujian Medical University
Clinicaltrials.gov ID:
Neals Affiliated?
No
Coordinating Center Contact Information
Qi-Jie Zhang, PhD / email hidden; JavaScript is required / 086-591-87982772
Full Study Summary:
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND), which is characterized with highly clinical heterogeneity and no effective treatment is available now. The purpose of this registered cohort is to observe the natural history of ALS patients in China, and then identify some factors correlated with disease progression. Besides, ALS-related gene mutations will be screened and explore novel disease causing gene as well.
Study Sponsor:
First Affiliated Hospital of Fujian Medical University
Estimated Enrollment:
2000
Estimated Study Start Date:
07 / 05 / 2019
Estimated Study Completion Date:
07 / 01 / 2059
Posting Last Modified Date:
03 / 22 / 2021
Date Study Added to neals.org:
07 / 05 / 2019
Minimum Age:
N/A
Maximum Age:
N/A
Inclusion Criteria:- Amyotrophic Lateral Sclerosis patients fulfilling the El Escorial criteria (including definite, probable and possible)
- Progressive muscular atrophy
- Primary lateral sclerosis
- Progressive bulbar palsy
Exclusion Criteria:
- History of serious head trauma or neuropsychiatric disease
- Decline to participate
Sub-Investigator : Wan-Jian Chen
Department of Neurology, First Affiliated Hospital of Fujian Medical University | Recruiting
Qi-Jie Zhang, PhD / 086-591-87982772 / email hidden; JavaScript is required
Ning Wang, PhD / 086-591-87982772 / email hidden; JavaScript is required
Principal Investigator : Ning Wang, MD,PhD
Fuzhou, Fujian
350005
China